Skip to main content
Log in

Sapropterin

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Sapropterin dihydrochloride (Kuvan; BioMarin) is a synthetic form of tetrahydrobiopterin, the natural cofactor for the enzyme phenylalanine hydroxylase (PAH). In December 2007, it became the first drug to be approved by the US FDA for the treatment of phenylketonuria, a genetic disorder that is characterized by PAH deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

References

  1. Scriver, C. R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 28, 831–845 (2007).

    Article  CAS  Google Scholar 

  2. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16–18, 2000. Pediatrics 108, 972–982 (2001).

  3. Blau, N. & Erlandsen, H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 82, 101–111 (2004).

    Article  CAS  Google Scholar 

  4. Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375–378 (1999).

    Article  CAS  Google Scholar 

  5. Muntau, A. C. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 347, 2122–2132 (2002).

    Article  CAS  Google Scholar 

  6. Food and Drug Administration. FDA labelling information [online], (2007).

  7. Burton, B. K. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a Phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 30, 700–707 (2007).

    Article  CAS  Google Scholar 

  8. Levy, H. L. et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a Phase III randomised placebo-controlled study. Lancet 370, 504–510 (2007).

    Article  CAS  Google Scholar 

  9. Waisbren, S. E. et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 92, 63–70 (2007).

    Article  CAS  Google Scholar 

  10. IMS, MIDAS Quantum (September 2007).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Barbara K. Burton has received research funding from BioMarin for clinical trials in PKU involving sapropterin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burton, B., Kar, S. & Kirkpatrick, P. Sapropterin. Nat Rev Drug Discov 7, 199–200 (2008). https://doi.org/10.1038/nrd2540

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2540

  • Springer Nature Limited

This article is cited by

Navigation